Featured Research

from universities, journals, and other organizations

Target-seeking Antibodies For Cancer Therapy

Date:
July 26, 2008
Source:
ETH Zurich/Swiss Federal Institute of Technology
Summary:
A chemist has discovered a new marker together with three associated monoclonal antibodies which are promising candidates for cancer therapy. Up to now, monoclonal antibodies have only aided the chemotherapeutic fight against cancer to a limited extent.

"Targeting" utilises antibodies as delivery vehicles to carry a medicine's active ingredients through the blood circulation and into the cancerous tumour. This enables healthy organs to be protected from harmful side-effects.
Credit: Image courtesy of ETH Zurich/Swiss Federal Institute of Technology

The chemist Dario Neri has carried out research for more than 15 years to find antibodies suitable as drug delivery vehicles for selective anti-cancer treatment. In his most recent publication he presents a new marker together with three associated monoclonal antibodies as further promising candidates for cancer therapy.

Up to now, monoclonal antibodies have only lived up to their expectations in the chemotherapeutic fight against cancer to a limited extent. Although these therapies are effective in prolonging the lives of patients who have types of cancer with a small chance of survival, for example advanced lung cancer, they cannot cure them. One of the main problems with current antibody chemotherapies is that the medicines lack selectivity. The active ingredients become distributed throughout the whole body and also attack healthy tissues in the liver, lungs or heart as well as the actual tumour that is to be treated.

Targeted anti-tumour treatment via the blood supply

By using “targeting”, Dario Neri from the Institute of Pharmaceutical Sciences at ETH Zurich has followed a promising path in cancer therapy. “Targeting” employs antibodies as delivery vehicles for medicines to carry their active ingredients through the blood circulation and into the tumour. Blood vessels that grow together with the tumour as a result of what is known as angiogenesis (neo-vascularization) and supply the tumour with nutrients enable drugs to be transported via the body’s own blood circulation and into the centre of the tumour.

The researchers use markers to help the antibodies find their way into the diseased cells. These markers can be thought of as a kind of antibody dock to which only proteins with specific characteristics can attach themselves. If the matching proteins are now loaded with an anti-cancer agent, the markers enable the drugs to be positioned highly selectively in the tumour as well as in the metastases, thus protecting the remainder of the healthy body. Among other things, Neri’s group is searching for such markers, i.e. protein characteristics that occur solely in the tumour’s blood circulatory system.

Neri’s colleague Luciano Zardi had already found such a marker 21 years ago in the shape of the extra-domain B (EDB) of the protein fibronectin. EDB is a variant of the fibronectin protein that occurs practically exclusively in the blood supply of tumours and their metastases. Today EDB is one of the best characterised markers in cancer research. In the past 10 years Neri and his team have developed two very promising antibodies, F16 und L19, that can “dock on to” tumour blood vessels and can be readily loaded with an anti-cancer active agent.

A large number of markers and antibodies is needed for therapy

In the “International Journal of Cancer”, Neri has described another marker, the fibronectin extra-domain A (EDA), together with three monoclonal antibodies that bind selectively to EDA. Explaining the relevance of the new results, Neri says, “Because each type of cancer has its own molecular characteristics, it is important that we make various different markers and antibodies available for therapy.” The publication describes the antibody F8 in particular as a promising candidate for this cancer therapy.

Tests on laboratory mice have shown that F8 accumulates very selectively in the tumour and in cancerous metastases, while healthy organs remain largely protected against the antibodies. According to Neri, “We believe that the F8 antibody could become an important building block in the development of selective and effective anti-cancer bio-pharmaceuticals.” Up to now, F8 has been tested only on mice. However, in collaboration with two pharmaceutical companies, clinical studies on humans are already taking place for the EDB antibodies F16 and L19, which have been known for longer. Initial results should be published soon, and, according to Neri, these are very promising. Neri says “We have good reason to assume that F8 could soon prove in clinical studies to be just as promising a cancer therapy candidate as F16 and L19.”


Story Source:

The above story is based on materials provided by ETH Zurich/Swiss Federal Institute of Technology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Villa A., Trachsel E., Kaspar M., Schliemann C., Sommavilla R., Rybak J.N., Rφsli C., Borsi L. and Neri D. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently target tumor neo-vasculature in vivo. Int J Cancer, Jun 1;122(11):2405-13 DOI: 10.1002/ijc.23408

Cite This Page:

ETH Zurich/Swiss Federal Institute of Technology. "Target-seeking Antibodies For Cancer Therapy." ScienceDaily. ScienceDaily, 26 July 2008. <www.sciencedaily.com/releases/2008/07/080720221517.htm>.
ETH Zurich/Swiss Federal Institute of Technology. (2008, July 26). Target-seeking Antibodies For Cancer Therapy. ScienceDaily. Retrieved September 16, 2014 from www.sciencedaily.com/releases/2008/07/080720221517.htm
ETH Zurich/Swiss Federal Institute of Technology. "Target-seeking Antibodies For Cancer Therapy." ScienceDaily. www.sciencedaily.com/releases/2008/07/080720221517.htm (accessed September 16, 2014).

Share This



More Health & Medicine News

Tuesday, September 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

EU Ministers and Experts Meet to Discuss Ebola Reponse

EU Ministers and Experts Meet to Discuss Ebola Reponse

AFP (Sep. 15, 2014) — The European Commission met on Monday to coordinate aid that the EU can offer to African countries affected by the Ebola outbreak. Duration: 00:58 Video provided by AFP
Powered by NewsLook.com
Despite The Risks, Antibiotics Still Overprescribed For Kids

Despite The Risks, Antibiotics Still Overprescribed For Kids

Newsy (Sep. 15, 2014) — A new study finds children are prescribed antibiotics twice as often as is necessary. Video provided by Newsy
Powered by NewsLook.com
FDA Eyes Skin Shocks Used at Mass. School

FDA Eyes Skin Shocks Used at Mass. School

AP (Sep. 15, 2014) — The FDA is considering whether to ban devices used by the Judge Rotenberg Educational Center in Canton, Massachusetts, the only place in the country known to use electrical skin shocks as aversive conditioning for aggressive patients. (Sept. 15) Video provided by AP
Powered by NewsLook.com
Respiratory Virus Spreads To Northeast, Now In 21 States

Respiratory Virus Spreads To Northeast, Now In 21 States

Newsy (Sep. 14, 2014) — The respiratory virus Enterovirus D68, which targets children, has spread from the Midwest to 21 states. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins